Assenagon Asset Management S.A. Cuts Holdings in Eli Lilly and Company $LLY

Key Points

• Assenagon Asset Management reduced its Eli Lilly stake by 67.7% in the second quarter, selling 1,049,209 shares and retaining 501,025 shares valued at approximately $600.9 million.
• Eli Lilly reported strong second-quarter results, with revenue rising 47.7% year over year to $22.97 billion and earnings per share of $8.38, well above analyst expectations.
• The company raised its 2026 revenue forecast to $85 billion–$87 billion as demand for Mounjaro and Zepbound remained strong. Analysts remain broadly bullish, with a “Moderate Buy” consensus rating and an average price target of $1,293.71.

Assenagon Asset Management S.A. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 67.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 501,025 shares of the company's stock after selling 1,049,209 shares during the period. Eli Lilly and Company makes up approximately 0.7% of Assenagon Asset Management S.A.'s portfolio, making the stock its 18th biggest holding. Assenagon Asset Management S.A. owned 0.05% of Eli Lilly and Company worth $600,944,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth about $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $30,000. Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after acquiring an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after acquiring an additional 24 shares in the last quarter. Finally, Aventus Investment Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after acquiring an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 1.9%

LLY opened at $1,191.87 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The business has a 50-day moving average of $1,157.76 and a two-hundred day moving average of $1,046.57. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 40.00, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 103.84% and a net margin of 33.53%.The business's quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above analysts’ expectations near $20.7 billion. Adjusted EPS of $8.38 substantially exceeded the consensus estimate of $6.16. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: Mounjaro sales reportedly surged 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly sales. The performance indicates that demand for Lilly’s diabetes and weight-loss treatments remains strong and is driving the company’s earnings growth. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $85 billion-$87 billion from $82 billion-$85 billion. Management also highlighted accelerating adoption of Foundayo, broader Medicare obesity-drug access and progress toward a potential 2027 retatrutide filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analyst optimism remains elevated: Cantor Fitzgerald raised its price target to $1,410 and maintained an “overweight” rating. Coverage also emphasizes that Lilly is widening its lead over Novo Nordisk, whose recent results have raised concerns about competitive momentum. The divide between Eli Lilly and Novo Nordisk is widening
• Neutral Sentiment: Amazon’s planned $50-per-month Medicare access to Wegovy, Zepbound and Foundayo could expand distribution and patient access, but greater retail availability may also increase price competition and payer pressure.
• Negative Sentiment: Several analysts caution that Lilly’s valuation and heavy reliance on GLP-1 products leave the shares vulnerable if demand, manufacturing capacity or competitive conditions weaken.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Sanford C. Bernstein upped their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. Wolfe Research reaffirmed an "outperform" rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. Barclays increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research note on Monday, May 4th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,293.71.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source